SCHEMBL2900760

SCHEMBL2900760

C=Cc1cc(C(=O)OC)c(Cl)c([N+](=O)[O-])c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
SIRT6 Q8N6T7 1/20 0.41
KDM4E B2RXH2 2/20 0.41
PDGFRB P09619 1/20 0.41
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT1 P17948 1/20 0.41
FGFR3 P22607 1/20 0.41
KDR P35968 1/20 0.41
MAPT P10636 4/20 0.39
MAPK1 P28482 3/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 3/20 0.37
VCAM1 P19320 1/20 0.37
GPR35 Q9HC97 1/20 0.37
DHODH Q02127 1/20 0.37
ALDH1A1 P00352 4/20 0.37
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12000739 0.81 TDP1 (0.49) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL2390718 0.80 SIRT6 (0.46) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL648496 0.80 SIRT6 (0.55) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL6626231 0.80 ALDH1A1 (0.46) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL2901232 0.78 TDP1 (0.47) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL9084161 0.78 PKM (0.44) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL15996997 0.77 PDGFRB (0.51) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL8064653 0.77 PDGFRB (0.48) MEN1KMT2ATDP1SIRT6KDM4E
SCHEMBL2895850 0.77 ABL1 (0.47) KDM4EMAPTPOLBALDH1A1
SCHEMBL19785891 0.72 XDH (0.47) MEN1KMT2ATDP1SIRT6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814537-B1 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-11-12 EP disclosed
US-7678783-B2 Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2010-03-16 US disclosed
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2008-10-30 US disclosed
CN-101133029-A Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease MERCK & CO INC (US) 2008-02-27 CN disclosed
EP-1814537-A2 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2007-08-08 EP disclosed
WO-2006055434-A2 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2006-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 MEN1 638/4885KMT2A 1848/4885TDP1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.